Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing.
Open accessThe DOI matches its OpenAlex record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Hereditary haemochromatosis (HH) is a disorder characterised by increase of serum iron parameters and gradual iron accumulation in parenchymal organs. Since the discovery of the genetic defects of the most common form of hereditary haemochromatosis (type 1 haemochromatosis [HFE]), many observations have shown that not only rare/familial mutations in HFE can be present but also that mutations in other genes (transferrin receptor 2 [TFR2], hepcidin [HAMP], hemojuvelin [HJV], and ferroportin [SLC40A1]) can lead to rarer genetic forms of iron overload, referred as non-HFE haemochromatosis1. The genetic heterogeneity is particularly evident in the Italian population where only two-thirds of haemochromatosis patients are HFE C282Y homozygotes2, requiring expensive and time-consuming gene specific genotyping to define the molecular diagnosis. Therefore, “second level” genetic tests should be developed for a rapid and simultaneous study of the haemochromatosis genes. The most common non-HFE haemochromatosis is the autosomal dominant haemochromatosis type 4 (HH4), caused by mutations in the SLC40A1 gene, encoding for cellular iron exporter ferroportin. Ferroportin acts as receptor of hepcidin, the key regulator of iron metabolism. The hepcidin/ferroportin interaction induces the internalisation of the complex, causing a decrease in iron export and its retention in the cell3. HH4 can be phenotypically classified in two groups: patients may have hyperferritinaemia with normal/low transferrin saturation (type-A HH4, ferroportin disease) or both serum iron parameters increased (type-B HH4, non-classical ferroportin disease)4. This depends on ferroportin impairment that could be classified as “loss-of-function” or “gain-of-function”. In the first case (type-A), the mutated protein is not expressed on the membrane and it is not able to exert its exporting function. In the second case (type-B), the mutated iron exporter becomes resistant to the activity of hepcidin, causing increased iron absorption. Several mutations have been characterised in HH4 patients, spreading along the entire gene sequence4. The position of the correspondent amino acidic change is important to define the HH4 clinical phenotype5. Among the different ferroportin mutations, the p.A69T variant, despite the causal nucleotide change not being annotated in dbSNP, has been described in a 52-year old Italian woman with diabetes and type-B HH4, on the basis of hepatocyte iron overload6, but no iron parameters or clinical history of the patient were described. The pathogenic role of this mutation has been subsequently confirmed through in vitro experiments in which mutant cDNA has been over-expressed7. These studies demonstrated that p.A69T mutated ferroportin has a partial resistance to hepcidin. Here we report an Italian patient with a severe iron overload phenotype in whom a careful clinical characterisation led to a diagnose of p.A69T non-classical ferroportin disease through the combination of capture of technology with a next generation sequencing (NGS) platform.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
Papanikolaou, G., Samuels, M. E., Ludwig, E. H., MacDonald, M. L. E., Franchini, P. L., Dubé, M.-P., Andres, L., MacFarlane, J., Sakellaropoulos, N., Politou, M., et al. (2004) · Nature Genetics · doi:10.1038/ng1274 · Cited by 974
Ferroportin disease: a systematic meta-analysis of clinical and molecular findings
Mayr, R., Janecke, A. R., Schranz, M., Griffiths, W. J. H., Vogel, W., Pietrangelo, A., & Zoller, H. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.016 · Cited by 133
Traglia, M., Girelli, D., Biino, G., Campostrini, N., Corbella, M., Sala, C., Masciullo, C., Viganò, F., Buetti, I., Pistis, G., et al. (2011) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100061 · Cited by 97
Self-citation
Cited by
Aschemeyer, S., Qiao, B., Stefanova, D., Valore, E. V., Sek, A. C., Ruwe, T. A., Vieth, K. R., Jung, G., Casu, C., Rivella, S., et al. (2018) · Blood · doi:10.1182/blood-2017-05-786590 · Cited by 325
Ferroportin disease: pathogenesis, diagnosis and treatment
Pietrangelo, A. (2017) · Haematologica · doi:10.3324/haematol.2017.170720 · Cited by 151
Zhang, D.-L., Ghosh, M. C., Ollivierre, H., Li, Y., & Rouault, T. A. (2018) · Blood · doi:10.1182/blood-2018-04-842997 · Cited by 107
Vlasveld, L. T., Janssen, R., Bardou-Jacquet, E., Venselaar, H., Hamdi-Roze, H., Drakesmith, H., & Swinkels, D. W. (2019) · Pharmaceuticals · doi:10.3390/ph12030132 · Cited by 57
“Sum: 7 GOF Hepcidin Sensitive: Neutral 12 7 3 Ala69Thr PM = – ↓! – 4 2 2 [42,51,52] Val72Phe PM = yes ↓! ↓binding 5 2 3 [30,53] Asn144Asp PM =# conflicting no# ↓binding/uptake 2 1 [30–32,35,54] Asn144His PM = conflicting yes ↓uptake 20 13 7 [3,6,31,34,35,39,40,42,55–59] Asn144Thr PM = conflicting yes# ↓uptake 1 1 [6,3…”
Background
Metadata
- Authors
- Ferbo, L., Manzini, P. M., Badar, S., Campostrini, N., Ferrarini, A., Delledonne, M., Francisci, T., Tassi, V., Valfrè, A., Dall'Omo, A. M., D’Antico, S., Girelli, D., Roetto, A., & Gobbi, M. D.
- Venue
- PubMed
- Publisher
- National Institutes of Health
- Published
- 2016-11-01
- Volume
- 14
- Issue
- 6
- Pages
- 531-534
- OpenAlex
- W2409433233
- Cited by
- 6
- References
- 3
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing. https://app.cochat.ai/papers/10.2450/2016.0286-15
- The paper
- Ferbo, L., Manzini, P. M., Badar, S., Campostrini, N., Ferrarini, A., Delledonne, M., Francisci, T., Tassi, V., Valfrè, A., Dall'Omo, A. M., D’Antico, S., Girelli, D., Roetto, A., & Gobbi, M. D. (2016). Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing. PubMed. https://doi.org/10.2450/2016.0286-15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.